Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc.
NASHVILLE, Tenn.—Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into a definitive agreement to acquire Tyrvaya (varenicline…
